Abstract
To assess the efficacy of single-dose antibiotic prophylaxis in coronary artery bypass grafting, 1,016 consecutive patients were prospectively randomized to receive either a single dose or a three-day course of cefuroxime. Nine patients (0.9 %) died within seven days; no death was caused by infection. For various reasons 163 other patients were not evaluable. Therefore, 844 patients were evaluated. Patients in group A (n=419) received 20 mg/kg cefuroxime intravenously at induction of anaesthesia; group B (n=425) received the same dose followed by 750 mg t.i.d. for three consecutive days. Both groups were comparable regarding all risk factors. The efficacy of the prophylactic regimens was evaluated by comparison of occurrence of wound infection in both groups. No significant differences in wound infection were observed between the two treatment groups: sternal site infection in the single-dose prophylaxis group was 14 % versus 13 % in the three-day course group; donor site infection occurred in 38 % versus 39 %. It is concluded that in coronary artery bypass grafting a single dose of cefuroxime is as effective as a three-day course in the prevention of wound infection.
Similar content being viewed by others
References
Fong IW, Baker CB, McKee DC The value of prophylactic antibiotics in aorta-coronary bypass operations. Journal of Thoracic and Cardiovascular Surgery 1979, 78: 908–913.
Penketh AR, Wansborough-Jones MH, Wright E, Imrie F, Pepper JR, Parloer DJ Antibiotic prophylaxis for coronary artery bypass graft surgery. Lancet 1985, i: 1500.
Slama TG, Sklar SJ, Misinski J, Fess SW Randomized comparison of cefamandole, cefazolin, and cefuroxime prophylaxis in open-heart surgery. Antimicrobial Agents and Chemotherapy 1986, 29: 744–747.
Peterson CD, Lake KD, Arom KV, Love KR Antibiotic prophylaxis in open-heart surgery patients: comparison of cefamandole and cefuroxime. Drug Intelligence and Clinical Pharmacy 1987, 21: 728–732.
Gentry LO, Zeluff BJ, Cooley DA Antibiotic prophylaxis in open heart surgery: a comparison of cefamandole, cefuroxime and cefazolin. Annals of Thoracic Surgery 1988, 46: 167–171.
Kouchoukos NT, Wareing TH, Murphy SF, Pelate C, Marshall WG Risk of bilateral internal mammary artery bypass grafting. Annals of Thoracic Surgery 1990, 49: 210–219.
Burke JF The effective period of preventive antibiotic action in experimental incisions and dermal lesions. Surgery 1961, 50: 161–168.
Koot MJ, IJdenberg FN, Stuurman RM, Poell J, Bras LJ, Langemeijer JJM, Lie-A-Huen L High pressure liquid chromatographic analysis of the serum concentration of cefuroxime after an intravenous bolus injection of cefuroxime in patients with a coronary artery bypass grafting. Pharmaceutisch Weekblad (Scientific edition) 1992, 14: 360–364.
Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes, JM CDC definitions for nosocomial infections, 1988. American Journal of Infection Control 1988, 16: 128–140.
Austin TW, Coles JC, Burnett R, Goldback M Aortocoronary bypass procedures and sternotomy infections: a study of antistaphylococcal prophylaxis. Canadian Journal of Surgery 1980, 23: 483.
Goldmann DA, Hopkins CC, Karchmer AW, Abel RM, McEnamy MT, Akins C, Buckley MJ, Moellering RC Cephalothin prophylaxis in cardiac valve surgery: a prospective, double-blind comparison of two-day and six-day regimens. Journal of Thoracic and Cardiovascular Surgery 1977, 73: 470–479.
Karchmer AW, Bisno AL Infections of prosthetic heart valves and vascular grafts. In: Bisno AL, Waldvogel FA (ed): Infections associated with indwelling medical devices. American Society for Microbiology, Washington DC, 1989, p. 129–159.
Scheld WM, Sande MA Endocarditis and intravascular infections. In Mandell GL, Douglas RG, Bennett JE (ed): Principles and practice of infectious diseases. Churchill Livingstone, New York, 1990, p. 670–706.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nooyen, S.M.H., Overbeek, B.P., Brutel de la Rivière, A. et al. Prospective randomised comparison of single-dose versus multiple-dose cefuroxime for prophylaxis in coronary artery bypass grafting. Eur. J. Clin. Microbiol. Infect. Dis. 13, 1033–1037 (1994). https://doi.org/10.1007/BF02111823
Issue Date:
DOI: https://doi.org/10.1007/BF02111823